Wednesday, December 18, 2002 6:41:26 PM
Leading Chemical Dependency Recovery Center Successfully Begins Treating Patients With CITA Biomedical's Innovative Treatments for Alcohol, Cocaine, And Crack Dependence LCM Chemical Dependency Recovery Center Treats First DNA for Addictions Patient for Alcoholism
BEVERLY HILLS, Calif., Dec. 16 /PRNewswire-FirstCall/ -- CITA Biomedical, Inc. (OTC Bulletin Board: DTOX) a growing leader in the treatment of addiction dependency, today announced that Little Company of Mary (LCM) Chemical Dependency Recovery Center in San Pedro, California successfully began treating patients using CITA's Detoxification and NeuroAdaptation (DNA) for Addictions family of treatments. The first patient was treated for alcoholism with CITA's DNA for Alcohol. The DNA for Addictions treatment family includes DNA for Alcohol, DNA for Alcohol and Cocaine, DNA for Cocaine, and DNA for Crack Cocaine. CITA has patents pending for the family of DNA treatments.
The patient, a 55-year-old male who had been dependant on alcohol for 43 years was treated with DNA for Alcohol. The patient was consuming an average of one quart of alcohol daily. "I've tried several programs including Betty Ford, St. Joseph's, and I've been in and out of AA," said the patient. "The DNA for Alcohol treatment is miraculous! I continue to have no desire to drink and can't even remember what alcohol tastes like." The treatment was administered to the patient for less than an hour daily over two consecutive days and he experienced no withdrawal symptoms.
DNA for Addictions establishes a new treatment regimen in the fight against drug addiction, a disorder that impedes normal neural functioning of the brain and body systems as a whole. Addiction causes cravings, possible brain damage, and can lead to potentially life-threatening withdrawal symptoms. Historically, the disorder of addiction has been treated only through behavioral intervention, but the CITA DNA treatment provides a solution for treating both the physiological and psychological components of this devastating disease.
DNA for Addictions patients experience a less than 25 percent relapse rate, compared to a more than 75 percent relapse rate generally associated other accepted means of treating addiction. The new treatment was also shown to reduce the time, pain, and costs associated with withdrawal, and allowed the patients to return to a productive level of functioning within hours of the treatment's completion.
"Now that we have multiple centers serving California we're ready to open centers across the United States," said Joseph Dunn, president and CEO of CITA Biomedical. "The patient testimonial from LCM Chemical Dependency Recovery Center is similar to comments from all our patients treated so far. Treating both the physical and psychological components of addiction are key to DNA for Addictions' success and what sets DNA apart from any other treatments."
About CITA Biomedical, Inc.
CITA Biomedical, Inc., headquartered in Beverly Hills, Calif., focuses on the innovative treatment of addiction. The company holds the U.S. patent for its successful UROD (Ultra Rapid Opiate Detoxification) treatment method. UROD is the only clinically tested and effective treatment method to rapidly detoxify individuals addicted to opiate-based drugs, including heroin within four to six hours with few, if any, withdrawal symptoms. The company has a new family of revolutionary treatments, Detoxification and NeuroAdaptation (DNA) for Addictions. The first treatments from this family treat alcohol, cocaine, crack, and poly-drug addictions. To date, CITA has grown its business through internal expansion and now seeks compatible, leading, and complementing technologies and acquisitions to enhance its corporate portfolio. CITA Biomedical, Inc. has two operating divisions CITA Americas, Inc., and AltTPro, Inc. For more information, please visit www.citabio.com
About Little Company of Mary Chemical Dependency Recovery Center
Little Company of Mary Chemical Dependency Recovery Center in San Pedro is a non-profit alcohol and drug rehabilitation center affiliated with Little Company of Mary -- an integrated regional health care system serving the South Bay and Harbor communities of Los Angeles. For more than 25 years, the center has provided a full range of rehabilitative services at our facility, located adjacent to San Pedro Peninsula Hospital.
UROD is a registered trademark of CITA Biomedical, Inc.
Contacts:
Investor Relations Treatment Information
CITA Biomedical, Inc. Call: 1-888-400-2482
Judy Ryon, 310-550-4971 or
jryon@citabio.com Visit: www.cita1.com
SOURCE CITA Biomedical, Inc.
CONTACT: Judy Ryon, Investor Relations of CITA Biomedical, Inc.,
+1-310-550-4971, jryon@citabio.com ; or Treatment Information,
+1-888-400-2482
Web site: http://www.citabio.com
http://www.cita1.com
.
Park your Sub at the iHub - Bub; .....the experience might just "...float your boat..." !!!
BEVERLY HILLS, Calif., Dec. 16 /PRNewswire-FirstCall/ -- CITA Biomedical, Inc. (OTC Bulletin Board: DTOX) a growing leader in the treatment of addiction dependency, today announced that Little Company of Mary (LCM) Chemical Dependency Recovery Center in San Pedro, California successfully began treating patients using CITA's Detoxification and NeuroAdaptation (DNA) for Addictions family of treatments. The first patient was treated for alcoholism with CITA's DNA for Alcohol. The DNA for Addictions treatment family includes DNA for Alcohol, DNA for Alcohol and Cocaine, DNA for Cocaine, and DNA for Crack Cocaine. CITA has patents pending for the family of DNA treatments.
The patient, a 55-year-old male who had been dependant on alcohol for 43 years was treated with DNA for Alcohol. The patient was consuming an average of one quart of alcohol daily. "I've tried several programs including Betty Ford, St. Joseph's, and I've been in and out of AA," said the patient. "The DNA for Alcohol treatment is miraculous! I continue to have no desire to drink and can't even remember what alcohol tastes like." The treatment was administered to the patient for less than an hour daily over two consecutive days and he experienced no withdrawal symptoms.
DNA for Addictions establishes a new treatment regimen in the fight against drug addiction, a disorder that impedes normal neural functioning of the brain and body systems as a whole. Addiction causes cravings, possible brain damage, and can lead to potentially life-threatening withdrawal symptoms. Historically, the disorder of addiction has been treated only through behavioral intervention, but the CITA DNA treatment provides a solution for treating both the physiological and psychological components of this devastating disease.
DNA for Addictions patients experience a less than 25 percent relapse rate, compared to a more than 75 percent relapse rate generally associated other accepted means of treating addiction. The new treatment was also shown to reduce the time, pain, and costs associated with withdrawal, and allowed the patients to return to a productive level of functioning within hours of the treatment's completion.
"Now that we have multiple centers serving California we're ready to open centers across the United States," said Joseph Dunn, president and CEO of CITA Biomedical. "The patient testimonial from LCM Chemical Dependency Recovery Center is similar to comments from all our patients treated so far. Treating both the physical and psychological components of addiction are key to DNA for Addictions' success and what sets DNA apart from any other treatments."
About CITA Biomedical, Inc.
CITA Biomedical, Inc., headquartered in Beverly Hills, Calif., focuses on the innovative treatment of addiction. The company holds the U.S. patent for its successful UROD (Ultra Rapid Opiate Detoxification) treatment method. UROD is the only clinically tested and effective treatment method to rapidly detoxify individuals addicted to opiate-based drugs, including heroin within four to six hours with few, if any, withdrawal symptoms. The company has a new family of revolutionary treatments, Detoxification and NeuroAdaptation (DNA) for Addictions. The first treatments from this family treat alcohol, cocaine, crack, and poly-drug addictions. To date, CITA has grown its business through internal expansion and now seeks compatible, leading, and complementing technologies and acquisitions to enhance its corporate portfolio. CITA Biomedical, Inc. has two operating divisions CITA Americas, Inc., and AltTPro, Inc. For more information, please visit www.citabio.com
About Little Company of Mary Chemical Dependency Recovery Center
Little Company of Mary Chemical Dependency Recovery Center in San Pedro is a non-profit alcohol and drug rehabilitation center affiliated with Little Company of Mary -- an integrated regional health care system serving the South Bay and Harbor communities of Los Angeles. For more than 25 years, the center has provided a full range of rehabilitative services at our facility, located adjacent to San Pedro Peninsula Hospital.
UROD is a registered trademark of CITA Biomedical, Inc.
Contacts:
Investor Relations Treatment Information
CITA Biomedical, Inc. Call: 1-888-400-2482
Judy Ryon, 310-550-4971 or
jryon@citabio.com Visit: www.cita1.com
SOURCE CITA Biomedical, Inc.
CONTACT: Judy Ryon, Investor Relations of CITA Biomedical, Inc.,
+1-310-550-4971, jryon@citabio.com ; or Treatment Information,
+1-888-400-2482
Web site: http://www.citabio.com
http://www.cita1.com
.
Park your Sub at the iHub - Bub; .....the experience might just "...float your boat..." !!!
.......According to the Great Pumpkin, ".....You're in .....iHub....., Charlie Brown....."!!!
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
